Oxaliplatin/5-fluorouracil in advanced hepatocellular carcinoma: case report and single-center retrospective review. (October 2014)

• Record Type: Journal Article
• Authors: Goldstein, Robert; Yu, Dominic; Gillmore, Roopinder; Thirlwell, Christina; O'Donoghue, Pam; Mayer, Astrid; Meyer, Tim
• Is Part Of: Future oncology. Volume 10:Number 13(2014)
• Page Start: 2007
• Page End: 2014
• Publication Date: 2014-10
• Subjects: FOLFOX -- hepatocellular carcinoma -- liver transplantation -- sorafenib; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.14.108
• Languages: English
• ISSNs: 1479-6694

Abstract

ABSTRACT : Aims: Sorafenib is the only standard therapy for advanced hepatocellular carcinoma, but has a low response rate. Leucovorin and oxaliplatin (FOLFOX) has a superior response rate versus doxorubicin among Asian sorafenib-naive patients. We aimed to retrospectively review the outcome of 20 consecutive patients treated with FOLFOX at a single European center.Materials & methods: Patients had symptomatic disease burdens unlikely to regress with sorafenib or had no proven treatment options (sorafenib-refractory or recurrence post liver transplantation).Results: One sorafenib-refractory patient had a complete response and two liver transplant patients experienced partial responses. Median overall survival was 6.3 months. There was one chemotherapy death due to neutropenic sepsis.Conclusion: In advanced hepatocellular carcinoma, FOLFOX can induce clinically relevant responses, but needs prospective validation.